- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
Sustainable Lifelines: Supporting Integrated Behavioral Health Services for Children and Adolescents in the Accountable Care EraA reimbursement strategy for collaborative care models is presented to enhance access to integrated behavioral healthcare for children and adolescents from underserved areas.
Latest:
Bending the Curve Through Health Reform ImplementationAuthors from The Brookings Institution update their recommendations by focusing on 3 concrete objectives to slow spending and improve quality of care within the next 5 years.
Latest:
Addressing Oncologists' Gaps in the Use of Biosimilar ProductsThe availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological products had been approved by the FDA, including 4 biosimilars for trastuzumab, 3 each for infliximab and adalimumab, 2 each for pegfilgrastim and filgrastim, and 1 each for rituximab, epoetin alfa, bevacizumab, and etanercept. The pace of approvals has accelerated, from the first indication for a filgrastim biosimilar in 2015 to 3 approvals in 2016, 5 in 2017, and 9 through early 2019, 7 of which were announced in the 2018 calendar year.
Latest:
Predictors of Physician Use of Inpatient Electronic Health RecordsHospital and physician-hospital alignment, but not loyalty, are predictors of integrated electronic health record adoption by admitting physicians in an integrated system.
Latest:
IT-Enabled Systems Engineering Approach to Monitoring and Reducing ADEsSelf-empowering team resource management, when aided by information technology, appears to help reduce adverse drug events in primary care offices.
Latest:
Continuous Quality Improvement Program, Based on Lean Concepts, Allows Emptying of Emergency Department CorridorsA continuous quality improvement program, based on Lean concepts and including architectural, managerial, and organizational features, allows the emptying of emergency department corridors and the improvement of time interval measurements/quality indicators.
Latest:
A Systematic Review of Value-Based Insurance Design in Chronic DiseasesValue-based insurance design for prescription drug coverage increases drug adherence in patients with chronic disease, though their effect on clinical outcomes and health spending remain uncertain.
Latest:
Hospitalized Patients' and Family Members' Preferences for Real-Time, Transparent Access to Their Hospital RecordsThis mixed-methods study evaluated hospitalized patients’ and family members’ perceived communications mismatches and their calls for transparent real-time information and potential 21st-century solutions.
Latest:
Using Administrative Claims to Identify Children With Chronic Conditions in a Statewide Immunization RegistryThis study examines the feasibility and utility of using administrative claims from commercial health plans to identify children with chronic conditions in a statewide registry.
Latest:
Alternative Payment Models and Hospital Engagement in Health Information ExchangeAlternative payment models (APMs) introduce value-based incentives for greater hospital health information exchange (HIE) engagement. We find that APM participation is associated with lower HIE volume and greater HIE diversity, breadth, and depth.
Latest:
Low-Value Care for Acute Sinusitis Encounters: Who's Choosing Wisely?Acute sinusitis is a common acute illness and offers an opportunity to eliminate low-value care. The authors describe current practices, comparing primary care, urgent care, and the emergency department.
Latest:
A Scoping Review of US Insurers’ Use of Patient-Reported OutcomesThis scoping review found 350 articles that discuss US health insurance providers’ use of patient-reported outcomes about health-related quality of life.
Latest:
Health of Medicare Advantage Plan Enrollees at 1 Year After Hurricane KatrinaAt 1 year after Hurricane Katrina, the health burden of enrollees increased significantly more versus a comparison group. Emergency department visits and hospitalizations remained elevated.
Latest:
Addressing Oncologists' Gaps in the Use of Biosimilar ProductsThe availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological products had been approved by the FDA, including 4 biosimilars for trastuzumab, 3 each for infliximab and adalimumab, 2 each for pegfilgrastim and filgrastim, and 1 each for rituximab, epoetin alfa, bevacizumab, and etanercept. The pace of approvals has accelerated, from the first indication for a filgrastim biosimilar in 2015 to 3 approvals in 2016, 5 in 2017, and 9 through early 2019, 7 of which were announced in the 2018 calendar year.
Latest:
Does a Personalized Approach Improve Patient Satisfaction in Thoracic Oncology?Evaluation of cancer patients’ quality of life at admission enabled improvement of their satisfaction with received care at discharge.
